Study guide

4.2 Sterile Preparations & Hazardous Drug Handling (NAPRA / NIOSH Principles)

PEBC Pharmacist Qualifying Examination Part I MCQ

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Canadian Pharmacy Regulatory Framework & Federal Legislation

1.1 Food and Drugs Act, Regulations, and Health Canada Oversight 1.2 Controlled Drugs and Substances Act (CDSA) & Controlled Substances Regulations (CSR) 1.3 NAPRA Drug Scheduling Framework & National Model Standards of Practice

2 Chapter 2: Ethics, Scope of Practice & Safety Culture

2.1 Professional Ethics, Fiduciary Duty & Health Information Privacy 2.2 Expanded Scope of Practice: Minor Ailments Prescribing, Renewals & Injections 2.3 Equity, Diversity, Inclusion, Cultural Safety & Continuous Quality Improvement

3 Chapter 3: Pharmaceutical Calculations & Posology

3.1 Concentrations, Dilutions, Alligations & Reconstitution 3.2 Dosing by Weight/BSA, Days Supply & Pediatric/Geriatric Dose Adjustments 3.3 IV Infusion Rates, Drop Factors, Osmolarity & Creatinine Clearance (Cockcroft-Gault)

4 Chapter 4: Compounding, Dispensing & Product Integrity

4.1 Non-Sterile Compounding & Beyond-Use Dating (NAPRA Standards) 4.2 Sterile Preparations & Hazardous Drug Handling (NAPRA / NIOSH Principles) 4.3 Prescription Verification, Auxiliary Labeling, Cold Chain & Medication Incident Prevention (ISMP Canada) 4.4 Dispensing Operations: Interchangeability, Adjudication, Compliance Packaging, Release & Inventory Control

5 Chapter 5: Clinical Pharmacology & Pharmacokinetics

5.1 Pharmacokinetic Principles: Clearance, Volume of Distribution, Half-life & Steady State 5.2 Cytochrome P450 Enzymes, Transporters & Significant Drug-Drug Interactions 5.3 Therapeutic Drug Monitoring (TDM), Narrow Therapeutic Index Drugs & Toxicities

6 Chapter 6: Evidence-Based Medicine & Literature Appraisal

6.1 Study Designs, Bias & Levels of Evidence in Clinical Research 6.2 Biostatistics: ARR, RRR, NNT, NNH, Confidence Intervals & P-values 6.3 Applying Canadian Practice Guidelines to Clinical Decision-Making 6.4 Drug Information Practice, Diagnostic Test Accuracy & Pharmacoeconomics

7 Chapter 7: Cardiovascular Pharmacotherapy: Hypertension, Dyslipidemia & CAD

7.1 Hypertension Management (Hypertension Canada Guidelines, Targets & Regimens) 7.2 Dyslipidemia & Atherosclerotic Cardiovascular Disease (CCS Guidelines & Statin Therapy) 7.3 Ischemic Heart Disease & Acute Coronary Syndromes (Antiplatelet & Antianginal Therapy)

8 Chapter 8: Cardiovascular Pharmacotherapy: Heart Failure, Arrhythmias & Anticoagulation

8.1 Heart Failure with Reduced & Preserved Ejection Fraction (GDMT & Monitoring) 8.2 Atrial Fibrillation, Arrhythmias & Rate vs. Rhythm Control 8.3 Venous Thromboembolism & Anticoagulation Therapy (DOACs, Warfarin & Thrombosis Canada)

9 Chapter 9: Endocrine & Metabolic Disorders

9.1 Type 2 Diabetes: Glycemic Targets, Non-Insulin Pharmacotherapy (Diabetes Canada) 9.2 Insulin Regimens, Type 1 Diabetes, Hypoglycemia & Diabetic Emergencies (DKA/HHS) 9.3 Thyroid Disorders & Osteoporosis (Diagnostic Parameters & Therapeutic Management)

10 Chapter 10: Respiratory & Gastrointestinal Disorders

10.1 Asthma Management & Exacerbations (CTS Guidelines, Relievers & Controllers) 10.2 Chronic Obstructive Pulmonary Disease (COPD) & Inhaler Delivery Systems 10.3 Gastroesophageal Reflux Disease (GERD), Peptic Ulcer Disease & GI Bleeding 10.4 Lower GI & Liver Disorders: Constipation, Diarrhea, IBS, IBD & Cirrhosis

11 Chapter 11: Infectious Diseases & Antimicrobial Stewardship

11.1 Respiratory Tract Infections: Otitis, Sinusitis, Pharyngitis, CAP & HAP 11.2 Urinary Tract, Skin/Soft Tissue & Sexually Transmitted Infections 11.3 Systemic Infections, Clostridioides difficile & Antimicrobial Stewardship Principles 11.4 HIV Prevention & Treatment, Viral Hepatitis, Tuberculosis & Fungal Infections

12 Chapter 12: Central Nervous System & Mental Health

12.1 Major Depressive Disorder & Anxiety Disorders (First-Line Agents & Safety) 12.2 Bipolar Disorder, Schizophrenia & Psychopharmacology Monitoring 12.3 Epilepsy, Seizure Types, Antiseizure Medications & Neuropathic Pain 12.4 Dementia, Parkinson Disease, Migraine, Insomnia & Restless Legs Syndrome

13 Chapter 13: Special Populations, Pain Management & Substance Use

13.1 Acute & Chronic Pain Management: Multimodal Analgesia & Opioid Stewardship 13.2 Substance Use Disorders: Opioid Agonist Therapy, Harm Reduction & Alcohol Withdrawal 13.3 Special Populations: Pharmacotherapy in Pregnancy, Lactation & Geriatrics (Deprescribing / Beers) 13.4 Palliative Care & Pediatric Pharmacotherapy

14 Chapter 14: Renal, Rheumatologic, Hematologic & Oncology Supportive Care

14.1 Chronic Kidney Disease, Acute Kidney Injury & Electrolyte Disorders 14.2 Osteoarthritis, Rheumatoid Arthritis & Gout 14.3 Anemias & Oncology Supportive Care

15 Chapter 15: Minor Ailments, Dermatology and Women's & Men's Health

15.1 Minor Ailments I: Allergic Rhinitis, Colds & Influenza, Eye and Ear Conditions 15.2 Minor Ailments II: Acne, Dermatitis, Psoriasis, Lice, Scabies & Sun Protection 15.3 Women's & Men's Health: Contraception, Emergency Contraception, Menopause, BPH, ED & Overactive Bladder

16 Chapter 16: Immunization & Health Promotion

16.1 Immunization Practice: NACI Recommendations, Administration, Cold Chain & Adverse Events 16.2 Health Promotion: Smoking Cessation, Weight Management, Screening & Social Determinants of Health

17 Chapter 17: Patient Care Process, Communication & Stewardship

17.1 The Patient Care Process: Assessment, Care Planning & Patient Interviewing 17.2 Patient Education, Device Counselling, Health Literacy & Overcoming Barriers 17.3 Interprofessional Collaboration, Pharmacy Workflow, Team Delegation & Drug Shortage Stewardship

4.2 Sterile Preparations & Hazardous Drug Handling (NAPRA / NIOSH Principles)

Key Takeaways Explain This Topic AI

Under NAPRA Model Standards for Sterile Compounding, the Direct Compounding Area (DCA) within a Primary Engineering Control (PEC) must maintain ISO Class 5 air quality (< 3,520 particles ≥ 0.5 μm/m³), situated within an ISO Class 7 Secondary Engineering Control (SEC) buffer room supplied by HEPA-filtered laminar airflow.

Cleanroom pressure gradients critically separate non-hazardous from hazardous operations: non-hazardous clean rooms stay at least +5.0 Pa (ideally 5.0 to 12.5 Pa) relative to the anteroom, whereas hazardous clean rooms stay at least -2.5 Pa relative to an ISO Class 7 anteroom, with external exhaust and at least 30 air changes per hour (ACPH).

Hazardous drugs categorized by NIOSH (antineoplastics, reproductive toxins, and organ-toxic agents) must be prepared in a certified Class II Biological Safety Cabinet (Type B2 total exhaust or externally vented Type A2) or Compounding Aseptic Containment Isolator (CACI), with Closed System Drug-Transfer Devices (CSTDs) as a supplementary control where policy requires them.

Personal protective equipment (PPE) garbing sequence strictly follows an anatomical progression from dirtiest to cleanest prior to entering the cleanroom: shoe covers, head and facial hair covers, face mask/eye shield, 30-second hand and forearm hygiene, non-shedding gown, hand disinfection with sterile 70% IPA, and finally sterile powder-free gloves (or two pairs of ASTM D6978 chemotherapy gloves for hazardous drugs).

Surface maintenance for hazardous drug cleanrooms mandates four distinct sequential chemical steps: deactivation (oxidizing agents like sodium hypochlorite to destroy chemical activity), decontamination (surfactants/water to remove residues), cleaning (germicidal detergents to remove dirt), and disinfection (sterile 70% IPA to eradicate viable microbes).

Last updated: October 2026

4.2 Sterile Preparations & Hazardous Drug Handling (NAPRA / NIOSH Principles)

Sterile compounding involves the preparation of therapeutic formulations free from microbial, particulate, pyrogenic, and chemical contamination. In Canada, sterile compounding is governed by the NAPRA Model Standards for Pharmacy Compounding of Sterile Preparations and the NAPRA Model Standards for Pharmacy Compounding of Hazardous Drugs . These regulatory benchmarks establish stringent requirements for facility architecture, air handling systems, aseptic personnel technique, personal protective equipment (PPE), and continuous environmental quality control.

Cleanroom Architecture & ISO Air Classifications

Cleanrooms control the concentration of airborne particulate matter to prevent contamination of sterile products. The International Organization for Standardization (ISO) classifies air cleanliness based on the maximum number of airborne particles ≥ 0.5 μ m \ge 0.5\ \mu\text{m} ≥ 0.5 μ m per cubic metre of air:

ISO Classification Conventional Name Max Particles ≥ 0.5 μ m/m 3 \ge 0.5\ \mu\text{m/m}^3 ≥ 0.5 μ m/m 3 Cleanroom Zone / Application

ISO Class 5 Class 100 3,520 Direct Compounding Area (DCA) inside Primary Engineering Controls (PECs: LAFW, BSC, CAI, CACI)

  • ISO Class 7 Class 10,000 352,000 Buffer Area (Cleanroom) ; Anteroom for hazardous sterile compounding
  • ISO Class 8 Class 100,000 3,520,000 Anteroom for non-hazardous sterile compounding; storage and garbing areas

Unclassified Ambient Room Air > 35 , 000 , 000 > 35,000,000 > 35 , 000 , 000 General hospital dispensary, packaging, or public retail areas Unclassified Area ---> ISO Class 8 Anteroom ---> ISO Class 7 Buffer Room ---> ISO Class 5 PEC (DCA)

  • [Dirtiest / Non-Sterile] [Cleanest / Critical Area]
  • Primary Engineering Controls (PECs) vs. Secondary Engineering Controls (SECs)

Primary Engineering Control (PEC): A certified device or room that provides an ISO Class 5 environment for compounding sterile preparations. PECs rely on High-Efficiency Particulate Air (HEPA) filters, which remove at least 99.97 % 99.97\% 99.97% of airborne particles with a size of 0.3 μ m 0.3\ \mu\text{m} 0.3 μ m or larger.

Secondary Engineering Control (SEC): The structural cleanroom suite housing the PEC, consisting of the buffer area (ISO Class 7) and the anteroom (ISO Class 7 or 8). The SEC provides controlled temperature (NAPRA: clean room and anteroom at or below 20 ∘ C 20^\circ\text{C} 2 0 ∘ C for personnel comfort in garb) and differential air pressure. NAPRA sets no relative humidity requirement.

Pressure Differentials: Non-Hazardous vs. Hazardous Cleanrooms

Air pressure differentials prevent the transfer of airborne contaminants between adjacent cleanroom suites. The direction of air movement is dictated by whether the drugs being manipulated pose toxicity risks to personnel: NON-HAZARDOUS STERILE FACILITY (Positive Pressure Regime):

  • [General Pharmacy] <--- [ISO Class 8 Anteroom] <--- [ISO Class 7 Buffer Room (PEC)]
  • (Ambient) (+5.0 to +12.5 Pa vs pharmacy) (+5.0 to +12.5 Pa vs anteroom)

*Air flows OUTWARD from cleanest area, preventing dust/microbes from entering.

HAZARDOUS STERILE FACILITY (Negative Pressure Regime):

  • [General Pharmacy] <--- [ISO Class 7 Anteroom] ---> [ISO Class 7 Buffer Room (C-PEC)]
  • (Ambient) (at least +5.0 Pa vs pharmacy) (at least -2.5 Pa vs anteroom)

*Air flows INWARD into the hazardous buffer room, preventing cytotoxic vapors from escaping.

1. Non-Hazardous Sterile Cleanrooms (Positive Pressure)

Pressure Gradient: The clean (buffer) room must maintain positive differential pressure of at least 5.0 Pa 5.0\text{ Pa} 5.0 Pa (ideally 5.0 5.0 5.0 to 12.5 Pa 12.5\text{ Pa} 12.5 Pa , about 0.02 0.02 0.02 to 0.05 0.05 0.05 inch water column) relative to the anteroom, and the ISO Class 8 anteroom must be positive by the same margin relative to the pharmacy.

Air Changes: At least 30 ACPH in the clean room and at least 20 ACPH in the anteroom.

Objective: If a door opens, clean, HEPA-filtered air rushes outward, preventing lower-quality ambient air, dust, and microorganisms from entering the cleanroom.

2. Hazardous Sterile Cleanrooms (Negative Pressure)

Pressure Gradient: The hazardous clean room (containment secondary engineering control, C-SEC) must maintain negative pressure of at least − 2.5 Pa -2.5\text{ Pa} − 2.5 Pa (about − 0.01 -0.01 − 0.01 inch water column) relative to the adjacent anteroom.

Objective: Prevents carcinogenic, teratogenic, and cytotoxic vapors, dusts, and aerosols from leaking into staff areas or the wider hospital.

Air Handling Requirements: The clean room and the anteroom must each provide at least 30 air changes per hour (ACPH) , and the clean room must be 100% externally vented through dedicated roof exhaust ducting. Air exhausted from hazardous compounding can never be recirculated into general HVAC systems.

Anteroom Configuration: The anteroom leading into a hazardous clean room must maintain an ISO Class 7 rating (not ISO Class 8) and must be at least + 5.0 Pa +5.0\text{ Pa} + 5.0 Pa relative to the pharmacy, so the anteroom acts as an air barrier between the clean room and the rest of the pharmacy.

Primary Engineering Controls (PECs) Compared

Different clinical preparations require specific PEC configurations to safeguard product sterility and personnel safety:

Primary Engineering Control (PEC) Airflow Direction Pressure Exhaust Mechanism Appropriate Clinical Uses

Horizontal Laminar Airflow Workbench (LAFW) Horizontal (from back HEPA filter toward operator) Positive Recirculates into buffer room Non-hazardous sterile compounding only (IV electrolytes, TPN, antibiotics). NEVER use for hazardous drugs!

Vertical Laminar Airflow Workbench (VLAFW) Vertical (from top HEPA filter downward toward work surface) Positive Recirculates into buffer room Non-hazardous sterile compounding only. Not acceptable for hazardous drugs without containment exhaust.

Class II Biological Safety Cabinet (BSC) Type A2 Vertical laminar flow with front air curtain Negative 70 % 70\% 70% recirculated through HEPA; 30 % 30\% 30% exhausted to exterior via canopy connection Hazardous drugs without volatile chemical or gaseous characteristics (e.g., antineoplastic reconstitution).

Class II Biological Safety Cabinet (BSC) Type B2 Vertical laminar flow with front air curtain Negative 100 % 100\% 100% total external exhaust (zero recirculation) Mandatory for volatile hazardous chemicals, radiopharmaceuticals, or gaseous antineoplastics.

Compounding Aseptic Isolator (CAI) Unidirectional / laminar Positive Recirculates or vents Non-hazardous sterile compounding in low-volume or satellite environments.

Compounding Aseptic Containment Isolator (CACI) Unidirectional / laminar Negative 100 % 100\% 100% externally exhausted Hazardous sterile compounding when a full cleanroom suite is structurally unavailable.

Caution

Using a Horizontal Laminar Airflow Workbench for compounding antineoplastic agents (such as methotrexate, doxorubicin, or cisplatin) is a catastrophic regulatory and safety violation. The horizontal airflow blows cytotoxic droplets and vapors directly into the operator's face and breathing zone.

NIOSH Hazardous Drug Lists & Closed System Transfer Devices (CSTDs)

The National Institute for Occupational Safety and Health (NIOSH) maintains the authoritative list of antineoplastic and other hazardous drugs in healthcare settings, categorized into three distinct groups:

Group 1: Antineoplastic Drugs: Cytotoxic chemotherapeutic agents that pose carcinogenic, mutagenic, or teratogenic risks (e.g., cisplatin, cyclophosphamide, doxorubicin, fluorouracil, methotrexate, paclitaxel, vincristine).

Group 2: Non-Antineoplastic Hazardous Drugs: Agents that meet one or more NIOSH toxicity criteria (e.g., organ toxicity at low doses, genotoxicity, carcinogenicity) but are not used primarily for cancer therapy (e.g., azathioprine, cyclosporine, tacrolimus, carbamazepine, spironolactone, ganciclovir, zidovudine).

Group 3: Non-Antineoplastic Drugs with Reproductive / Developmental Effects: Agents that impair fertility or cause fetal harm during pregnancy/lactation (e.g., finasteride, dutasteride, letrozole, misoprostol, mifepristone, ribavirin, thalidomide, warfarin).

Closed System Drug-Transfer Devices (CSTDs)

A Closed System Drug-Transfer Device (CSTD) is a drug-transfer device that mechanically prohibits the transfer of environmental contaminants into the system and the escape of hazardous drug or vapor concentrations outside the system. CSTDs employ physical double-membrane puncture seals or internal equalization chambers with toxic vapor filters.

Where the requirement comes from: USP <800> in the United States requires CSTDs for administering antineoplastic hazardous drugs when the dosage form allows. NAPRA's hazardous sterile standard does not impose a general CSTD mandate; many Canadian oncology programs adopt CSTDs through provincial or institutional policy. A CSTD is a supplementary control used inside a certified BSC or CACI. It never replaces the ISO Class 5 C-PEC.

NAPRA Beyond-Use Dates for Sterile Preparations

When no stability or sterility data support a longer period, NAPRA's non-hazardous sterile standard sets maximum beyond-use dates by contamination risk level and storage condition:

  • Risk level Room temperature Refrigerated (2°C–8°C) Frozen (−25°C to −10°C)
  • Low (simple transfers of sterile products, few manipulations) 48 hours 14 days 45 days
  • Medium (multiple doses or pooled ingredients, complex manipulations such as TPN) 30 hours 9 days 45 days

High (non-sterile ingredients, or exposure to air worse than ISO Class 5 before sterilization) 24 hours 3 days 45 days

Preparations made in a segregated ISO Class 5 LAFW outside a clean room carry a beyond-use time of 12 hours or less . A preparation made for immediate use in an emergency must begin administration within 1 hour of the start of preparation.

Personal Protective Equipment (PPE) & Garbing Protocol

Personnel represent the single greatest source of particulate and microbial contamination in cleanroom environments. Personnel shed thousands of skin squames, respiratory droplets, and microbes per minute. Therefore, garbing must follow a strict sequential progression from dirtiest to cleanest anatomical locations prior to entering the buffer room. GARBING PROGRESSION (OUTSIDE-IN)

[STEP 1: ANTEROOM - DIRTY SIDE]

1. Remove all jewelry, watches, rings, cosmetics, and outer jackets.

2. Don dedicated cleanroom shoe covers (one foot at a time, crossing the line of demarcation).

3. Don head and facial hair covers (ensuring all hair and ears are fully enclosed).

4. Don surgical face mask and protective eye shield / safety goggles.

  • [STEP 2: ANTEROOM - CLEAN SIDE / SINK]
  • 5. Perform aseptic hand hygiene: Wash hands and forearms up to the elbows with warm water
  • and antimicrobial soap for at least 30 seconds. Clean underneath fingernails with a disposable

nail pick. Dry completely with disposable, lint-free towels.

6. Don a non-shedding, lint-free disposable gown with snug knit cuffs and a high neck closure.

[STEP 3: BUFFER ROOM / DIRECT COMPOUNDING AREA]

7. Enter the ISO Class 7 buffer room.

8. Disinfect hands with alcohol-based hand rub containing 70% sterile isopropanol (IPA); allow to dry.

9. Don sterile, powder-free gloves over the gown cuffs.

10. For hazardous drugs: Don TWO pairs of ASTM D6978 chemotherapy gloves (inner pair under cuff,

outer pair over cuff). Routinely disinfect outer gloves with sterile 70% IPA.

Important

For hazardous drug compounding, gowns must be disposable, polyethylene-coated (poly-coated) or laminately impermeable to liquid penetration, and closed in the back. Standard cloth lab coats or permeable non-coated sterile gowns are strictly prohibited because cytotoxic liquids seep through porous fibers into contact with skin.

Cleanroom Maintenance: Deactivation, Decontamination, Cleaning & Disinfection

Cleaning and sanitizing hazardous drug compounding areas requires four distinct, non-interchangeable chemical actions performed in a precise sequential order:

Deactivation: Renders the chemical compound inert or non-toxic through chemical oxidation or destruction. Typical agents include sodium hypochlorite (safety data sheets often recommend a 2% solution; because it corrodes stainless steel, a neutralizer such as sodium thiosulfate or a detergent rinse follows) or accelerated hydrogen peroxide . Quaternary ammonium compounds and alcohol cannot deactivate hazardous drugs.

Decontamination: Neutralizes, inactivates, or physically lifts and removes hazardous chemical residues from surfaces. Typical agents include sterile water, surfactants, or alcohol solutions.

Cleaning: Physically removes organic and inorganic soil, dirt, and microbial biofilms using a germicidal detergent solution.

Disinfection: Destroys viable vegetative microorganisms and fungi on inanimate surfaces using sterile 70 % 70\% 70% isopropanol (IPA) . The sterile IPA must remain wet on the surface for its specified contact time (typically 30 seconds to 1 minute) and allowed to air dry. Deactivation (Bleach/Peroxide) ---> Decontamination (Surfactant) ---> Cleaning (Detergent) ---> Disinfection (Sterile 70% IPA)

Hazardous Spill Management Protocol

When a hazardous drug spill occurs in the pharmacy:

Alert and Evacuate: Immediately warn everyone in the immediate area. Evacuate non-essential personnel and post warning signs.

Obtain Spill Kit: Retrieve the dedicated hazardous drug spill kit and don specialized PPE: NIOSH-certified N95 or Powered Air-Purifying Respirator (PAPR), chemical splash goggles, double chemotherapy gloves, and heavy-duty poly-coated chemotherapy gown.

Contain the Spill: Cover liquid spills gently with absorbent spill pads to prevent spreading. For powder spills, place damp absorbent towels over the powder to prevent aerosolization.

Clean and Deactivate: Work from the periphery of the spill toward the center. Decontaminate the surface using oxidizing deactivating solution, followed by detergent and sterile water.

Waste Disposal: Dispose of all contaminated glass, pads, and PPE into yellow, puncture-resistant cytotoxic biohazard waste containers marked for high-temperature incineration.

Document: File a formal incident report detailing the drug, estimated volume, cause, and any personnel exposure.